• 1
    Francis JL, Biggerstaff J, Amirkhosravi A. Hemostasis and malignancy. Semin Thromb Hemost 1998;24:93109.
  • 2
    Rickles FR. Mechanisms of cancer-induced thrombosis in cancer. Pathophysiol Haemost Thromb 2006;35:103110.
  • 3
    Lecumberri R, Paramo JA, Rocha E. Anticoagulant treatment and survival in cancer patients. The evidence from clinical studies. Haematologica 2005;90:12581266.
  • 4
    Madewell BR, Feldman BF, O'Neill S. Coagulation abnormalities in dogs with neoplastic disease. Thromb Haemost 1980;44:3538.
  • 5
    O'Donnell MR, Slichter SJ, Weiden PL, Storb R. Platelet and fibrinogen kinetics in canine tumors. Cancer Res 1981;41:13791383.
  • 6
    Grindem CB, Breitschwerdt EB, Corbett WT, et al. Thrombocytopenia associated with neoplasia in dogs. J Vet Intern Med 1994;8:400405.
  • 7
    Helfand S. Platelets and neoplasia. Vet Clin North Am Small Anim Pract 1988;18:131156.
  • 8
    O'Keefe D, Couto G. Coagulation abnormalities associated with neoplasia. Vet Clin North Am Small Anim Pract 1988;18:157168.
  • 9
    Hammer AS, Couto CG, Swardson C, Getzy D. Hemostatic abnormalities in dogs with hemangiosarcoma. J Vet Intern Med 1991;5:1114.
  • 10
    Hargis AM, Feldman BF. Evaluation of hemostatic defects secondary to vascular tumors in dogs: 11 cases (1983–1988). J Am Vet Med Assoc 1991;198:891864.
  • 11
    Maruyama H, Miura T, Sakai M, et al. The incidence of disseminated intravascular coagulation in dogs with malignant tumor. J Vet Med Sci 2004;66:573575.
  • 12
    McNiel EA, Ogilvie GK, Fettman MJ, Salman MD. Platelet hyperfunction in dogs with malignancies. J Vet Intern Med 1997;11:178182.
  • 13
    Thomas JS, Rogers KS. Platelet aggregation and adenosine triphosphate secretion in dogs with untreated multicentric lymphoma. J Vet Intern Med 1999;13:319322.
  • 14
    Mischke R, Freund M, Leinemann-Fink T, et al. Changes in hemostasis of dogs with acute lymphoblastic leukaemia. Berl Munch Tierarztl Wochenschr 1998;111:5359.
  • 15
    Mischke R, Wohlsein P, Busse L, Pohlenz J. Disseminated intravascular coagulation and hyperfibrinolysis in dogs with metastasizing mammary carcinoma. Schweiz Arch Tierheilkd 1998;140:497505.
  • 16
    Stockhaus C, Kohn B, Rudolph R, et al. Correlation of haemostatic abnormalities with tumour stage and characteristics in dogs with mammary carcinoma. J Small Anim Pract 1999;40:326331.
  • 17
    Johnson LR, Lappin MR, Baker DC. Pulmonary thromboembolism in 29 dogs: 1985–1995. J Vet Intern Med 1999;13:338345.
  • 18
    LaRue MJ, Murtaugh MJ. Pulmonary thromboembolism in dogs: 47 cases (1986–1987). J Am Vet Med Assoc 1990;197:13681372.
  • 19
    Van Winkle TJ, Bruce E. Thrombosis of the portal vein in eleven dogs. Vet Pathol 1993;30:2835.
  • 20
    Ruf W. Molecular regulation of blood clotting in tumor biology. Haemostasis 2001;31:57.
  • 21
    Ruf W, Mueller BM. Thrombin generation and the pathogenesis of cancer. Semin Thromb Hemost 2006;32 (Suppl 1):6168.
  • 22
    Mueller BM, Ruf W. Requirement for binding of catalytically active factor VIIa in tissue factor-dependent experimental metastasis. J Clin Invest 1998;101:13721378.
  • 23
    Rak J, Milsom C, May L, et al. Tissue factor in cancer and angiogenesis: The molecular link between genetic tumor progression, tumor neovascularization, and cancer coagulopathy. Semin Thromb Hemost 2006;32:5470.
  • 24
    Amirkhosravi A, Mousa SA, Amaya M, Francis JL. Antimetastatic effect of tinzaparin, a low-molecular-weight heparin. J Thromb Haemost 2003;1:19721976.
  • 25
    Amirkhosravi A, Meyer T, Chang JY, et al. Tissue factor pathway inhibitor reduces experimental lung metastasis of B16 melanoma. Thromb Haemost 2002;87:930936.
  • 26
    Langer F, Amirkhosravi A, Ingersoll SB, et al. Experimental metastasis and primary tumor growth in mice with hemophilia A. J Thromb Haemost 2006;4:10561062.
  • 27
    Banke IJ, Arlt MJ, Mueller MM, et al. Effective inhibition of experimental metastasis and prolongation of survival in mice by a potent factor Xa-specific synthetic serine protease inhibitor with weak anticoagulant activity. Thromb Haemost 2005;94:10841093.
  • 28
    Lopez-Pedrera C, Barbarroja N, Dorado G, et al. Tissue factor as an effector of angiogenesis and tumor progression in hematological malignancies. Leukemia 2006;20:13311340, epub May 25, 2006.
  • 29
    Nelson OL, Andreasen C. The utility of plasma D-dimer to identify thromboembolic disease in dogs. J Vet Intern Med 2003;17:830834.
  • 30
    Griffin A, Callan MB, Shoter FS, et al. Evaluation of a canine D-dimer point-of-care test kit for use in samples obtained from dogs with disseminated intravascular coagulation, thromboembolic disease, and hemorrhage. Am J Vet Res 2003;64:15621569.
  • 31
    Wiinberg B, Jensen AL, Rojkjaer R, et al. Validation of human recombinant tissue factor activated thromboelastography on citrated whole blood from clinically healthy dogs. Vet Clin Pathol 2005;34:389393.
  • 32
    Wiinberg B, Jensen AL, Kjelgaard-Hansen M, et al. Study on biological variation of hemostatic parameters in clinically healthy dogs. Vet J 2007;174:6268.
  • 33
    Otto CM, Rieser TM, Brooks MB, Russel MW. Evidence of hypercoagulability in dogs with parvoviral enteritis. J Am Vet Med Assoc 2000;217:15001504.
  • 34
    McCrath DJ, Cerboni E, Frumento RJ, et al. Thrombo-elastography maximum amplitude predicts postoperative thrombotic complications including myocardial infarction. Anesth Analg 2005;100:15761583.
  • 35
    Gurbel PA, Bliden KP, Guyer K, et al. Platelet reactivity in patients and recurrent events post-stenting: Results of the PREPARE POST-STENTING Study. J Am Coll Cardiol 2005;46:18201826.
  • 36
    Drake TA, Morrisey JH, Edgington TS. Selective cellular expression of tissue factor in human tissues. Am J Pathol 1989;134:10871097.